Determination of Immune Phenotype in Glioblastoma Patients

University of Ulm

Status: Completed

Conditions: Glioblastoma Multiforme

Treatments: Procedure: Surgery

Study type: Observational

Funder types: Other

Identifiers

NCT02751138

University Hospital Ulm

Details and patient eligibility

About

Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults. Despite intensive research efforts and a multimodal management that actually consists of surgery, radiotherapy and chemotherapy with temozolomide, the prognosis is dismal. The aim of the current observational study is to determine immune phenotypes in individual patients with GBM at the time of diagnosis and to correlate tumor size, location (imaging), tumor properties (isocitrate dehydrogenase - 1 (IDH-1), o6-methylguanine-DNA-methyltransferase (MGMT), epidermal growth factor receptor (EGFR) mutation status, etc.) with clinical data, such as progression free and overall survival, Karnofsky index (progression free survival (PFS),overall survival (OS), Karnofsky score( KFS)), with blood immune phenotypes, biomarkers, and immune histochemical results of tumor infiltrating lymphocytes, macrophages, myeloid derived suppressor cells (MDSC), etc.. The different immunological phenotypes could predict a positive response to specific immunological therapeutic strategies and select the individual therapeutic plan for an individual GBM patient.

Enrollment: 100 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• adult glioblastoma multiforme

Exclusion criteria

• pregnancy, unable to give consent

Trial design

100 participants in 2 patient groups

Isocitrate dehydrogenase - 1 mutated

Description:

Immunophenotype of Glioblastoma and correlation with outcome

Treatment:

Procedure: Surgery

Isocitrate dehydrogenase - 1 wild type

Description:

Immunophenotype of Glioblastoma and correlation with outcome

Treatment:

Procedure: Surgery